Show simple item record

dc.contributor.authorDíaz-de-Terán, Javier
dc.contributor.authorMembrilla, Javier A.
dc.contributor.authorPaz-Solís, José
dc.contributor.authorde Lorenzo, Iñigo
dc.contributor.authorRoa, Javier
dc.contributor.authorLara-Lara, Manuel
dc.contributor.authorGil-Martínez, Alfonso
dc.contributor.authorDíez Tejedor, Exuperio 
dc.date.accessioned2022-10-14T11:23:19Z
dc.date.available2022-10-14T11:23:19Z
dc.date.issued2021-02-13
dc.identifier.citationBrain sciences 11.2 (2021): 236en_US
dc.identifier.issn2076-3425es_ES
dc.identifier.urihttp://hdl.handle.net/10486/704516
dc.description.abstractOccipital nerve stimulation (ONS) is a surgical treatment proposed for drug-resistant chronic cluster headache (drCCH). Long-term series assessing its efficacy are scarce. We designed a retrospective observational study with consecutive sampling, evaluating the follow-up of 17 drCCH patients who underwent ONS. Our main endpoint was the reduction the rate of attacks per week. We also evaluated the pain intensity through the Visual Analogue Scale (VAS), patient overall perceived improvement and decrease in oral medication intake. After a median follow-up of 6.0 years (4.5-9.0), patients decreased from a median of 30 weekly attacks to 22.5 (5.6-37.5, p = 0.012), 7.5 at 1 year (p = 0.006) and 15.0 at the end of follow-up (p = 0.041). The VAS decreased from a median of 10.0 to 8.0 (p = 0.011) at three months, to 7.0 (p = 0.008) at twelve months and 7.0 (p = 0.003) at the end of the follow-up. A total of 23.5% had an overall perceived improvement of ≥ 70% at 3 months, 41.2% at 1 year and 27.8% at the end of follow-up. Reducing prophylactic oral medication was possible in 76,5% and it was stopped in 17.7%. Triptan use decreased in all the responder patients and 17.7% stopped its intake. A total of 41.2% presented mild adverse events. In conclusion, our long-term experience suggests that ONS could be an interesting option for drCCH-selected patients, as it is a beneficial and minimally invasive procedure with no serious adverse events.en_US
dc.description.sponsorshipPublication costs and financial support for medical writing were provided by Boston Scientific. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.en_US
dc.format.extent11 pag.es_ES
dc.format.mimetypeapplication/pdfen_US
dc.language.isoengen_US
dc.publisherBasel: MDPI AGen_US
dc.relation.ispartofBrain Sciencesen_US
dc.rights© 2021 by the authorsen_US
dc.subject.otherChronicen_US
dc.subject.otherCluster headacheen_US
dc.subject.otherDrug-resistanten_US
dc.subject.otherNeuromodulationen_US
dc.subject.otherOccipital nerve stimulationen_US
dc.subject.otherRefractoryen_US
dc.titleOccipital nerve stimulation for pain modulation in drug-resistant chronic cluster headacheen_US
dc.typearticleen_US
dc.subject.ecienciaMedicinaes_ES
dc.identifier.publicationfirstpage236-1es_ES
dc.identifier.publicationissue2es_ES
dc.identifier.publicationlastpage236-11es_ES
dc.identifier.publicationvolume11es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen_US
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen_US
dc.facultadUAMFacultad de Medicinaes_ES
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record